NEWS
BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin
BioVie Inc. (NASDAQ: BIVI) has received a Notice of Allowance from the USPTO for a patent application covering a novel liquid formulation of terlipressin acetate. This formulation demonstrates room-temperature stability for up to 24 months and can be packaged in a pre-filled syringe. The patent is expected to be listed in the Orange Book and supports BioVie's development of a more patient-centric ambulatory treatment for patients with ascites and hepatic failure.
The liquid formulation offers significant advantages over the recently approved lyophilized powder form of terlipressin in the US, which requires reconstitution and refrigerated storage. BioVie's formulation could improve dosing convenience and safety, particularly in home-care settings. The company has also secured patents for this formulation in India and Chile, with applications pending in nine additional markets.
The liquid formulation offers significant advantages over the recently approved lyophilized powder form of terlipressin in the US, which requires reconstitution and refrigerated storage. BioVie's formulation could improve dosing convenience and safety, particularly in home-care settings. The company has also secured patents for this formulation in India and Chile, with applications pending in nine additional markets.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1693Followers
93Following
13KVisitors
Follow